BIOXYTRAN, INC

BIXT | $0.123 490.75% 34K

(0.0% 1d) (10.6% 1m) (-73.5% 1y) (0.0% 2d) (8.3% 3d) (-10.8% 7d) (-5.67% volume)
Earnings Calendar:
Market Cap: $ 21,399,789
https://www.bioxytraninc.com/
Sec Filling | Patents | 3 employees

(US) bioxytran, inc., an early stage pharmaceutical company, focuses on the development, manufacture, and commercialization of various therapeutic drugs to address hypoxia in humans. the company's lead pharmaceutical drug candidate is bxt-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for the treatment of patients with ischemia of the brain resulting from a stroke or the blockage of the blood vessels to the brain. its products also include bxt-252, an injectable anti-necrosis drug to treat a wound that does not heal because limited amount of oxygen reaching the wound. the company was founded in 2017 and is headquartered in newton, massachusetts.

injection

add to watch list Paper trade email alert is off

Press-releases

Bioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 Antagonist
Published: 2024-03-06 (Crawled : 14:00) - globenewswire.com
BIXT | $0.123 490.75% 34K

Professional, Scientific, and T...

| 23.81% | O: 4.76% H: 33.64% C: 9.09%
galectin-3 clearance study

Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19
Published: 2024-02-21 (Crawled : 13:00) - globenewswire.com
BIXT | $0.123 490.75% 34K

Professional, Scientific, and T...

| 11.21% | O: 0.0% H: 0.09% C: -5.9%
covid-19 drug antiviral trial

Bioxytran Gets Broad Patent Coverage on 60+ Viruses
Published: 2023-10-24 (Crawled : 12:30) - globenewswire.com
BIXT | $0.123 490.75% 34K

Professional, Scientific, and T...

| -23.35% | O: 10.02% H: 0.0% C: -8.9%
patent

Bioxytran Interview at the Emerging Growth Conference
Published: 2023-10-04 (Crawled : 13:00) - globenewswire.com
BIXT | $0.123 490.75% 34K

Professional, Scientific, and T...

| -7.87% | O: 11.62% H: 11.11% C: 1.65%
conference growth

Bioxytran Announces Broad Spectrum Antiviral Activity Highlighted in ProLectin-M
Published: 2023-09-14 (Crawled : 14:00) - globenewswire.com
BIXT | $0.123 490.75% 34K

Professional, Scientific, and T...

| -31.58% | O: -5.26% H: 0.0% C: -16.67%
antiviral

Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials
Published: 2023-08-24 (Crawled : 13:00) - globenewswire.com
BIXT | $0.123 490.75% 34K

Professional, Scientific, and T...

| -24.51% | O: 15.56% H: 0.5% C: -4.77%
fda clearance trials application

Bioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 Patients
Published: 2023-08-08 (Crawled : 11:00) - globenewswire.com
BIXT | $0.123 490.75% 34K

Professional, Scientific, and T...

| -1.66% | O: -8.77% H: 13.02% C: 12.77%
covid-19 trial

Bioxytran Names Leslie Ajayi as Interim CMO and Head of the Medical Advisory Board
Published: 2023-07-31 (Crawled : 11:00) - globenewswire.com
BIXT | $0.123 490.75% 34K

Professional, Scientific, and T...

| 4.0% | O: 8.08% H: 10.66% C: 10.66%
cmo medical

Friday Footnotes: Big 4 CEO Hype Songs; Tim Ryan Does Sit-Ups For Breakfast; SEC on SPAC | 6.30.23 – Going Concern
Published: 2023-06-30 (Crawled : 21:00) - spacfeed.com
BIXT | $0.123 490.75% 34K

Professional, Scientific, and T...

| Email alert Add to watchlist
USCT | $11.23 0.27% 12K

n/a

| Email alert Add to watchlist
ceo spac

S-4/A – Anzu Special Acquisition Corp I (0001840877) (Filer)
Published: 2023-06-30 (Crawled : 21:00) - spacfeed.com
BIXT | $0.123 490.75% 34K

Professional, Scientific, and T...

| Email alert Add to watchlist
USCT | $11.23 0.27% 12K

n/a

| Email alert Add to watchlist
acquisition

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001445815-24-000009	4	2024-03-27	2024-03-27	Buy	A	266955	874576
0001445815-24-000008	4	2024-03-27	2024-03-27	Buy	A	266955	855476
0001445815-24-000007	4	2024-03-27	2024-03-27	Buy	A	439595	20133018
0001445815-24-000006	4	2024-03-27	2024-03-27	Buy	A	266955	928776